George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical trials. The mRNA HIV vaccine aims to block the replication of HIV strains and stimulate the production of broadly neutralizing antibodies that control the virus within HIV-positive patients’ immune systems. Read more by clicking the link!
University administers first doses of mRNA HIV vaccine through Moderna partnership
Latest News
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.
It's National Immunization Awareness Month! Getting vaccinated on the recommended schedule is an important part of protecting against many diseases. Please check with your trusted provider to see what vaccines are recommended for you!